玻璃体内注射布罗珠单抗治疗放射性黄斑病变继发顽固性黄斑囊样水肿后的短期疗效
Short-term outcomes following treatment of recalcitrant cystoid macular edema secondary to radiation maculopathy using intravitreal brolucizumab.
作者信息
Corradetti Giulia, Corvi Federico, Juhn Alexander, Sadda SriniVas R
机构信息
Doheny Eye Institute, University of California Los Angeles (UCLA), 1355 San Pablo Street, Los Angeles, CA, United States.
Retina Disorders and Ophthalmic Genetics, Stein Eye Institute, University of California-Los Angeles, 100 Stein Plaza Dr, Los Angeles, CA, United States.
出版信息
Am J Ophthalmol Case Rep. 2020 Oct 26;20:100981. doi: 10.1016/j.ajoc.2020.100981. eCollection 2020 Dec.
PURPOSE
To assess the efficacy of intravitreal brolucizumab (Beovu®, Novartis Pharmaceuticals) in a case of recalcitrant cystoid macular edema associated with radiation maculopathy secondary to retinoblastoma which was suboptimally responsive to other intravitreal anti-vascular endothelial growth factor (VEGF) therapies.
OBSERVATIONS
A 42-year old patient with a history of radiation maculopathy complicated by cystoid macular edema after chemoreduction treatment and radiation therapy for retinoblastoma was treated with intravitreal brolucizumab. Best-corrected visual acuity and central macular thickness assessed by optical coherence tomography were used to assess the clinical outcomes. The treated eye was also assessed for evidence of intraocular inflammation following injection. Cystoid macular edema showed marked reduction and near resolution two weeks after injection and improvement in best-corrected visual acuity which was maintained for 2 months of follow-up. No ocular inflammatory reactions or other adverse events were reported.
CONCLUSIONS AND IMPORTANCE
This case of radiation maculopathy refractory to other intravitreal anti-VEGF treatments showed good treatment response to brolucizumab therapy.
目的
评估玻璃体内注射布罗卢izumab（Beovu®，诺华制药）治疗视网膜母细胞瘤继发放射性黄斑病变相关顽固性黄斑囊样水肿的疗效，该患者对其他玻璃体内抗血管内皮生长因子（VEGF）治疗反应欠佳。
观察结果
一名42岁患者，既往有视网膜母细胞瘤化疗减瘤治疗和放射治疗后并发放射性黄斑病变及黄斑囊样水肿病史，接受了玻璃体内注射布罗卢izumab治疗。采用最佳矫正视力和光学相干断层扫描评估的中心黄斑厚度来评估临床疗效。还对治疗眼注射后眼内炎症证据进行了评估。注射后两周，黄斑囊样水肿明显减轻且接近消退，最佳矫正视力改善，并在2个月的随访期内保持稳定。未报告眼部炎症反应或其他不良事件。
结论与意义
该例对其他玻璃体内抗VEGF治疗难治的放射性黄斑病变，对布罗卢izumab治疗显示出良好的治疗反应。
Zotero 插件